Neurosearch denies share manipulation charges
COPENHAGEN (Reuters) - Danish biopharma firm Neurosearch A/S said on Wednesday charges of share price manipulation had been filed against it, but it denied the allegations and said it was working with the authorities to clear up the matter.
Neurosearch said the charges were related to an announcement in February 2010 in which the management of the company reported top-line results from a Phase III study with its Huntington's disease drug candidate Huntexil and then two months later reassessed and corrected the data in a new announcement.
"On the present basis, Neurosearch is denying the charges and is collaborating fully with the authorities in order to resolve the matter," the company said in a statement.
(Reporting by John Acher)
- Tweet this
- Share this
- Digg this
- Malaysian jetliner may have turned back before vanishing
- Malaysian jet's disappearance among rarest of aviation disasters
- Malaysian plane still missing; questions over false IDs
- Malaysia Airlines says "fearing the worst" for missing jet
- WRAPUP 6-Malaysian jetliner may have turned back before vanishing
When President Bill Clinton announced in 2000 that Craig Venter and Dr. Francis Collins of the National Human Genome Research Institute had succeeded in mapping the human genome, he solemnly declared that the discovery would "revolutionize" the treatment of virtually all human disease. Full Article